Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2-Reference-Cited by-同舟云学术

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2

Published:2017-11 Issue:2 Volume:147 Page:267-275
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Oza Amit M.,Tinker Anna V.,Oaknin Ana,Shapira-Frommer Ronnie,McNeish Iain A.,Swisher Elizabeth M.,Ray-Coquard Isabelle,Bell-McGuinn Katherine,Coleman Robert L.,O'Malley David M.,Leary Alexandra,Chen Lee-may,Provencher Diane,Ma Ling,Brenton James D.,Konecny Gottfried E.,Castro Cesar M.,Giordano Heidi,Maloney Lara,Goble Sandra,Lin Kevin K.,Sun James,Raponi Mitch,Rolfe Lindsey,Kristeleit Rebecca S.

Funder

NIHR

Wellcome UCH Clinical research Facility

UCL Experimental Cancer Medicine Centre

Clovis Oncology, Inc

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference28 articles.

1. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development;Scott;J Clin Oncol,2015

2. DNA repair pathways as targets for cancer therapy;Helleday;Nat Rev Cancer,2008